CAS: 159912-53-5; (3Z,3R)-N-Methoxy-1-Azabicyclo[2.2.2]Octane-3-Carboximidoyl Cyanide

上下游产品

(+/-) Skb20206 151433-82-8
(Z)-N-Methoxy-1-Azabicyclo[2.2.2]Octane-3-Carboximidoyl Chloride 155613-14-2

📜奎宁环-3-羧酸置于吡啶,四氯化碳,氯化亚砜,三苯基膦体系中,用 二氯甲烷,氯仿,二甲基亚砜,乙腈 用作溶剂,化学反应 13.33H,反应生成沙可美林
参考文献:Design Of [r-(Z)]-(+)-α-(Methoxyimino)-1-Azabicyclo[2.2.2]octane-3-Acetonitrile (Sb 202026),A Functionally Selective Azabicyclic Muscarinic M1 Agonist Incorporating The N-Methoxy Imidoyl Nitrile Group As A Novel Ester Bioisostere
标题:Design Of [r-(Z)]-(+)-α-(Methoxyimino)-1-Azabicyclo[2.2.2]octane-3-Acetonitrile (Sb 202026),A Functionally Selective Azabicyclic Muscarinic M1 Agonist Incorporating The N-Methoxy Imidoyl Nitrile Group As A Novel Ester Bioisostere
摘要:Loss Of Cholinergic Function Is Believed To Be Implicated In The Cognitive Decline Associated With Senile Dementia Of The Alzheimer Type (Sdat). The Disease Is Characterized By Progressive Loss Of Muscarinic Receptors Located On Nerve Terminals While Postsynaptic Muscarinic M1 Receptors Appear To Remain Largely Intact. Muscarinic Agonists Acting Directly On Postsynaptic Receptors Offer The Prospect Of Countering The Cholinergic Deficit In Sdat. This Study Describes A Novel Series Of Azabicyclic Muscarinic Agonists,Which Incorporate An Oxime Ether Or Modified Oxime Ether Group As An Ester Bioisostere. Modification Of The Oxime Ether Function By The Introduction Of Electron Withdrawing Groups Led To The Finding That The (Z)-N-Methoxy Imidoyl Nitrile Group Serves As A Stable Methyl Ester Bioisostere. This Culminated In The Discovery Of The Quinuclidinyl N-Methoxy Imidoyl Nitrile R-(+)-(Z)-5G Which Is A Functionally Selective Muscarinic M1 Partial Agonist Currently In Phase Iii Clinical Trials For The Treatment Of Sdat. The Selective Profile Of R-(+)-(Z)-5G Can Be Rationalized In Terms Of The Relative Affinity Of The Compound At Muscarinic Receptor Subtypes,The Degree Of Agonist Efficacy,And Brain Penetrancy.
Doi:10.1021/jm9702903

专利信息

专利号:US-2012190648-A1
优先权日:2009-07-23
标 题:Fluorinated cyclopropane analogs of glutamic acid
发明人：JUBAULT PHILIPPE; QUIRION JEAN-CHARLES; LEMONNIER GERALD; LION CEDRIC
权利人:JUBAULT PHILIPPE; QUIRION JEAN-CHARLES; LEMONNIER GERALD; LION CEDRIC
摘要:The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a mixture in all proportions of stereoisomers thereof, in particular a mixture of enantiomers, such as a racemic mixture, wherein R represents a (C 1 -C 6 )alkyl or (C 1 -C 6 )alkenyl group, optionally substituted by one or more groups chosen among an halogen atom, OR a , SR b , NR c R d , PO(OR e )(OR f ), CO 2 R g , SO 2 R h SO 3 R 1 , P0(0H)(CH(0H)R k ), CN, N 3 and NH—C(â•?NH)NH2, with R a , R b , R c and R d , representing, independently of each other, an hydrogen atom, a (C 1 -C 6 )alkyl group or a —CO—(C 1 -C 6 )alkyl group, R e , R f , R g , R h and R1 representing, independently of each other, an hydrogen atom or a (C 1 -C 6 )alkyl group, and R k representing an aryl or heteroaryl group, said group being optionally substituted by one or more groups selected from an halogen atom and NO 2 , as well as to the use thereof and to a process for preparing such a compound, to a pharmaceutical composition containing it and to synthesis intermediates.

专利号:US-9751877-B2
优先权日:2012-09-21
标题 :Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders
发明人：PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; PATEL NANDINI CHATURBHAI; STIFF CORY MICHAEL; TRAN TUAN PHONG; KAUFFMAN GREGORY WAYNE; STEPAN ANTONIA FRIEDERIKE; VERHOEST PATRICK ROBERT
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:WO-2025030095-A1
优先权日:2023-08-03
标 题 :Methods of synthesis
发明人：DERSTINE BRENDEN PAUL; TUCKER JOHN LLOYD
权利人:NEUROCRINE BIOSCIENCES INC
摘要:This present disclosure relates to processes for preparing a compound of Formula (A) which is useful as an intermediate in the preparation of mAChR agonist compounds; and compositions comprising the compound of Formula (A).

专利号:WO-2012172449-A1
优先权日:2011-06-13
标题:Lactams as beta secretase inhibitors
发明人：BRODNEY MICHAEL AARON
权利人:PFIZER; BRODNEY MICHAEL AARON
摘要:Compound and pharmaceutically acceptable salts of the compound are disclosed, wherein the compound has the structure (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed. The compound of formula I is useful as beta secretase inhibitor for use in the treatment of Alzheimer's and other neurodegenerative and/or neurological disorders.

专利号:US-2016229847-A1
优先权日:2013-10-04
标 题:Novel bicyclic pyridinones as gamma-secretase modulators
发明人：PETTERSSON MARTIN YOUNGJIN; AM ENDE CHRISTOPHER WILLIAM; GREEN MICHAEL ERIC; JOHNSON DOUGLAS SCOTT; KAUFFMAN GREGORY WAYNE; O'DONNELL CHRISTOPHER WILLIAM; PATEL NANDINI CHATURBHAI; STEPAN ANTONIA FRIEDERIKE; STIFF CORY MICHAEL; SUBRAMANYAM CHAKRAPANI; TRAN TUAN PHONG; VERHOEST PATRICK ROBERT
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula II as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-9067934-B2
优先权日:2011-03-31
标题 :Bicyclic pyridinones
发明人：PETTERSSON MARTIN YOUNGJIN; JOHNSON DOUGLAS SCOTT; SUBRAMANYAM CHAKRAPANI; O'DONNELL CHRISTOPHER JOHN; AM ENDE CHRISTOPHER WILLIAM; FISH BENJAMIN ADAM; GREEN MICHAEL ERIC; MULLINS PATRICK BRADLEY; STIFF CORY MICHAEL; TRAN TUAN PHONG; NAVARATNAM THAYALAN
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n nas defined herein. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.